Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 251

Similar articles for PubMed (Select 22849743)

1.

Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP.

Arch Pathol Lab Med. 2012 Aug;136(8):935-46. doi: 10.5858/arpa.2011-0424-OA.

2.

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, Chen L, Magi-Galluzzi C, Zhou M.

Am J Surg Pathol. 2011 Jul;35(7):1062-8. doi: 10.1097/PAS.0b013e318215cc03.

PMID:
21623182
3.

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.

He H, Osunkoya AO, Carver P, Falzarano S, Klein E, Magi-Galluzzi C, Zhou M.

BJU Int. 2012 Dec;110(11 Pt B):E751-5. doi: 10.1111/j.1464-410X.2012.11557.x. Epub 2012 Oct 9.

PMID:
23046279
4.

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M.

Am J Surg Pathol. 2011 Apr;35(4):608-14. doi: 10.1097/PAS.0b013e31820bcd2d.

PMID:
21383613
5.

Antibody-based detection of ERG rearrangement-positive prostate cancer.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA.

Neoplasia. 2010 Jul;12(7):590-8.

6.

ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.

Gao X, Li LY, Zhou FJ, Xie KJ, Shao CK, Su ZL, Sun QP, Chen MK, Pang J, Zhou XF, Qiu JG, Wen XQ, Yang M, Bai XZ, Zhang H, Ling L, Chen Z.

Clin Cancer Res. 2012 Aug 1;18(15):4163-72. Epub 2012 Jun 13.

7.

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J.

Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15.

8.

Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.

Shah RB.

Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Review.

PMID:
23399797
9.

The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.

Shah RB, Tadros Y, Brummell B, Zhou M.

Hum Pathol. 2013 May;44(5):786-94. doi: 10.1016/j.humpath.2012.06.024. Epub 2012 Nov 14.

PMID:
23158212
10.

Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.

Stewart J, Fleshner N, Cole H, Toi A, Sweet J.

J Urol. 2008 May;179(5):1751-5; discussion 1755. doi: 10.1016/j.juro.2008.01.012. Epub 2008 Mar 17.

PMID:
18343427
11.

Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer.

Mertz KD, Horcic M, Hailemariam S, D'Antonio A, Dirnhofer S, Hartmann A, Agaimy A, Eppenberger-Castori S, Obermann E, Cathomas G, Bubendorf L.

Hum Pathol. 2013 Dec;44(12):2727-35. doi: 10.1016/j.humpath.2013.07.019. Epub 2013 Sep 26.

PMID:
24074533
12.

TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA.

J Clin Oncol. 2014 Jan 20;32(3):206-11. doi: 10.1200/JCO.2013.49.8386. Epub 2013 Dec 2.

13.

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.

14.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

15.

ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB.

Am J Surg Pathol. 2010 Apr;34(4):478-85. doi: 10.1097/PAS.0b013e3181d6827b.

PMID:
20220513
16.

Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.

Stewart J, Fleshner N, Cole H, Sweet J.

J Clin Pathol. 2007 Jul;60(7):773-80. Epub 2006 Aug 17.

18.

Use of immunohistochemistry in routine workup of prostate needle biopsies: a tertiary academic institution experience.

Watson K, Wang C, Yilmaz A, Bismar TA, Trpkov K.

Arch Pathol Lab Med. 2013 Apr;137(4):541-5. doi: 10.5858/arpa.2012-0145-OA. Epub 2012 Dec 28.

PMID:
23273390
19.

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.

Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194.

20.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk